December 13, 2021 07:15 AM EST

Generic drugs and biosimilars get last-minute reprieve from rebates with Senate tweaks to Build Back Better Act

Zachary Brennan

Senior Editor

The Senate Finance Committee on Saturday released the latest text of President Joe Biden’s $2 trillion spending package, paid for at least in part with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Generic drugs and biosimilars get last-minute reprieve from rebates with Senate tweaks to Build Back Better Act

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Biogen gets $250M in Royalty Pharma deal for Phase 3 lupus program

After passing on M&A offers, Abcuro raises $200M in bid to become commercial drugmaker

Exclusive: Longevity startup targets renegade proteins linked to diabetes and obesity

SpringWorks lands FDA approval for nerve tumor treatment

What will pharma's share buyback shopping spree mean for M&A?

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Gener­ic drugs and biosim­i­lars get last-minute re­prieve from re­bates with Sen­ate tweaks to Build Back Bet­ter Act

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Generic drugs and biosimilars get last-minute reprieve from rebates with Senate tweaks to Build Back Better Act